EMA hands Italy's Chiesi a win in its long campaign to advance new drugs for rare diseases
Five years after Italy’s Chiesi built up its rare disease efforts through acquiring Zymenex, the EMA has come through with a marketing OK for a drug obtained in that deal.
Lamzede is an enzyme replacement therapy for the ultra-rare alpha-mannosidosis, a multi-faceted debilitating disease that is estimated to affect 470 people in the EU. The treatment is approved specifically for non-neurological manifestations in patients with mild to moderate forms of the disorder, a first for this patient population.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
